These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25530171)

  • 1. Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis.
    O'Dwyer DN; Armstrong ME; Kooblall M; Donnelly SC
    Expert Opin Ther Targets; 2015 Apr; 19(4):507-14. PubMed ID: 25530171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis.
    O'Dwyer DN; Armstrong ME; Trujillo G; Cooke G; Keane MP; Fallon PG; Simpson AJ; Millar AB; McGrath EE; Whyte MK; Hirani N; Hogaboam CM; Donnelly SC
    Am J Respir Crit Care Med; 2013 Dec; 188(12):1442-50. PubMed ID: 24070541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis.
    Samara KD; Antoniou KM; Karagiannis K; Margaritopoulos G; Lasithiotaki I; Koutala E; Siafakas NM
    Int J Oncol; 2012 May; 40(5):1397-404. PubMed ID: 22344343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptors in the pathogenesis of pulmonary fibrosis.
    Karampitsakos T; Woolard T; Bouros D; Tzouvelekis A
    Eur J Pharmacol; 2017 Aug; 808():35-43. PubMed ID: 27364757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of idiopathic pulmonary fibrosis.
    Sergew A; Brown KK
    Expert Opin Emerg Drugs; 2015; 20(4):537-52. PubMed ID: 26629731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutics based on emerging concepts in pulmonary fibrosis.
    Sontake V; Gajjala PR; Kasam RK; Madala SK
    Expert Opin Ther Targets; 2019 Jan; 23(1):69-81. PubMed ID: 30468628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained activation of toll-like receptor 9 induces an invasive phenotype in lung fibroblasts: possible implications in idiopathic pulmonary fibrosis.
    Kirillov V; Siler JT; Ramadass M; Ge L; Davis J; Grant G; Nathan SD; Jarai G; Trujillo G
    Am J Pathol; 2015 Apr; 185(4):943-57. PubMed ID: 25660181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristic patterns in the fibrotic lung. Comparing idiopathic pulmonary fibrosis with chronic lung allograft dysfunction.
    Fernandez IE; Heinzelmann K; Verleden S; Eickelberg O
    Ann Am Thorac Soc; 2015 Mar; 12 Suppl 1():S34-41. PubMed ID: 25830833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IPF: new insight on pathogenesis and treatment.
    Harari S; Caminati A
    Allergy; 2010 May; 65(5):537-53. PubMed ID: 20121758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing.
    Toonkel RL; Hare JM; Matthay MA; Glassberg MK
    Am J Respir Crit Care Med; 2013 Jul; 188(2):133-40. PubMed ID: 23306542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targets and early stage clinical trials for pulmonary fibrosis.
    Sato S; Yanagihara T; Kolb MRJ
    Expert Opin Investig Drugs; 2019 Jan; 28(1):19-28. PubMed ID: 30513000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?
    Huie TJ; Brown KK
    Respir Investig; 2015 May; 53(3):88-92. PubMed ID: 25951093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
    McElroy AN; Invernizzi R; Laskowska JW; O'Neill A; Doroudian M; Moghoofei M; Mostafaei S; Li F; Przybylski AA; O'Dwyer DN; Bowie AG; Fallon PG; Maher TM; Hogaboam CM; Molyneaux PL; Hirani N; Armstrong ME; Donnelly SC
    Am J Respir Crit Care Med; 2022 Mar; 205(5):550-562. PubMed ID: 34985402
    [No Abstract]   [Full Text] [Related]  

  • 14. Idiopathic pulmonary fibrosis.
    Adkins JM; Collard HR
    Semin Respir Crit Care Med; 2012 Oct; 33(5):433-9. PubMed ID: 23001798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of Aging-Dependent MicroRNAs in Idiopathic Pulmonary Fibrosis.
    Nho RS
    Drug Dev Res; 2015 Nov; 76(7):343-53. PubMed ID: 26303294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer.
    Vancheri C; du Bois RM
    Eur Respir J; 2013 Feb; 41(2):262-9. PubMed ID: 22903965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine.
    Maher TM
    Curr Opin Pulm Med; 2013 Sep; 19(5):460-5. PubMed ID: 23912190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.
    Huang Y; Ma SF; Espindola MS; Vij R; Oldham JM; Huffnagle GB; Erb-Downward JR; Flaherty KR; Moore BB; White ES; Zhou T; Li J; Lussier YA; Han MK; Kaminski N; Garcia JGN; Hogaboam CM; Martinez FJ; Noth I;
    Am J Respir Crit Care Med; 2017 Jul; 196(2):208-219. PubMed ID: 28157391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic pulmonary fibrosis landscapes: looking glass from pathology to therapy.
    Stella GM; Balestro E
    Minerva Med; 2015 Aug; 106(4 Suppl 3):17-24. PubMed ID: 27427121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biomarkers in idiopathic pulmonary fibrosis.
    Ley B; Brown KK; Collard HR
    Am J Physiol Lung Cell Mol Physiol; 2014 Nov; 307(9):L681-91. PubMed ID: 25260757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.